Keywords : Peripheral Neuropathy, cancer
This report provides data on the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy). 'Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H1 2012' is built using data and information sourced from Global Industrie...
More »
Search ReportLinker
The Largest Collection of Market Research Reports
» 1.2 Million Industry Reports
» 450,000 Company Profiles
» 850,000 Market Briefings
» 40,000 Country Guides
From +200,000 authoritative sources
This report provides data on the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy). 'Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H1 2012' is built using data and information sourced from Global Industries Direct’s proprietary databases, Firms /University websites, SEC filings, investor presentations and featured press releases from firm /university sites and market -specific third party sources, put together by Global Industries Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope of the Research
- A snapshot of the global therapeutic scenario for Peripheral Neuropathy (Sensory Neuropathy).
- A review of the Peripheral Neuropathy (Sensory Neuropathy) products under development by industry players and universities/research institutes based on information derived from industry player and market -specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Peripheral Neuropathy (Sensory Neuropathy) pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage new product development featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Peripheral Neuropathy (Sensory Neuropathy).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and take over s effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Peripheral Neuropathy (Sensory Neuropathy) pipeline depth and focus of Peripheral Neuropathy (Sensory Neuropathy) therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and grow business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Global Pathology Industry
Table of Contents
Data table of Contents
Data table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global March kets Direct Report Coverage 6
Peripheral Neuropathy (Sensory Neuropathy) Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Peripheral Neuropathy (Sensory Neuropathy) 8
Peripheral Neuropathy (Sensory Neuropathy) Therapeutics under Development by Firms 10
Peripheral Neuropathy (Sensory Neuropathy) Therapeutics under Investigation by Universities/Institutes 11
Late Stage Products 13
Comparative Analysis 13
Mid Clinical Stage Products 14
Comparative Analysis 14
Discovery and Pre-Clinical Stage Products 15
Comparative Analysis 15
Peripheral Neuropathy (Sensory Neuropathy) Therapeutics – Products under Development by Firms 16
Peripheral Neuropathy (Sensory Neuropathy) Therapeutics – Products under Investigation by Universities/Institutes 17
Companies Involved in Peripheral Neuropathy (Sensory Neuropathy) Therapeutics Development 18
NsGene A/S 18
Bayer AG 19
Allon Therapeutics Inc. 20
Spectrum Pharmaceuticals, Inc. 21
CeNeRx BioPharma, Inc. 22
Peripheral Neuropathy (Sensory Neuropathy) – Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Combination Products 24
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
SPI-205 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
AL-309 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
NsG31 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
March ijuana - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Amifostine trihydrate - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Amifostine Trihydrate - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Sagopilone + Acetyl-L-Carnitine + Prednisone - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 36
Amitriptyline + Ketamine - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Glutamine - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Rituximab - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
CXB040 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
CXB070 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Carboplatin + Glutathione + Paclitaxel - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Duloxetine - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Pregabalin - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
CXB006 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
CNSB015 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Peripheral Neuropathy (Sensory Neuropathy) Therapeutics – Drug Profile Updates 48
Peripheral Neuropathy (Sensory Neuropathy) Therapeutics – Discontinued Products 49
Peripheral Neuropathy (Sensory Neuropathy) Therapeutics - Dormant Products 50
Peripheral Neuropathy (Sensory Neuropathy) – Product Development Milestones 51
Featured News & Press Releases 51
February 09, 2011: CeNeRx Receives FDA IND Approval For CXB909 51
February 07, 2011: EpiCept Reports Positive Results From EpiCept NP-1 Trial In Patients With Chemotherapy-Induced Peripheral Neuropathy 51
September 08, 2010: DARA Announces Phase III Trial Results Of KRN5500 In Patients With Chemotherapy Induced Peripheral Neuropathy And Advanced Cancer 52
June 11, 2010: Pfizer, Eisai to launch postherpetic neuralgia drug Lyrica Capsules on 22 53
June 11, 2010: Pfizer, Eisai to launch postherpetic neuralgia drug Lyrica Capsules on 22 53
May 28, 2010: Relevare Pharmaceuticals Presents Latest Clinical Trial Data On CNSB015 At Third International Congress On Neuropathic Pain In Athens, Greece 53
April 06, 2010: Pfizer told to Pay US$ 142.1 million for Neurontin industry ing violations. 54
December 20, 2009: CNSBio Inc. To Present Latest Clinical Trial Data For CNSB015 At Neuropathic Pain Conference in San Francisco 54
November 18, 2009: NeoPharm Presents LE-DT Phase I Data At The AACR Conference 55
October 14, 2009: Newron Returns Rights to HF0420 55
Appendix 56
Methodology 56
Coverage 56
Secondary Research 56
Primary Research 56
Expert Panel Validation 56
Contact Us 57
Disclaimer 57
List of Tables
List of Tables
Number of Products Under Development for Peripheral Neuropathy (Sensory Neuropathy), H1 2012 8
Products under Development for Peripheral Neuropathy (Sensory Neuropathy) – Comparative Analysis, H1 2012 9
Number of Products under Development by Firms, H1 2012 10
Number of Products under Investigation by Universities/Institutes, H1 2012 12
Comparative Analysis by Late Stage Development, H1 2012 13
Comparative Analysis by Mid Clinical Stage Development, H1 2012 14
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012 15
Products under Development by Firms, H1 2012 16
Products under Investigation by Universities/Institutes, H1 2012 17
NsGene A/S, H1 2012 18
Bayer AG, H1 2012 19
Allon Therapeutics Inc., H1 2012 20
Spectrum Pharmaceuticals, Inc., H1 2012 21
CeNeRx BioPharma, Inc., H1 2012 22
Assessment by Monotherapy Products, H1 2012 23
Assessment by Combination Products, H1 2012 24
Assessment by Stage and Route of Administration, H1 2012 26
Assessment by Stage and Molecule Type, H1 2012 28
Peripheral Neuropathy (Sensory Neuropathy) Therapeutics – Drug Profile Updates 48
Peripheral Neuropathy (Sensory Neuropathy) Therapeutics – Discontinued Products 49
Peripheral Neuropathy (Sensory Neuropathy) Therapeutics – Dormant Products 50
List of Figures
List of Figures
Number of Products under Development for Peripheral Neuropathy (Sensory Neuropathy), H1 2012 8
Products under Development for Peripheral Neuropathy (Sensory Neuropathy) – Comparative Analysis, H1 2012 9
Products under Development by Firms, H1 2012 10
Products under Investigation by Universities/Institutes, H1 2012 11
Late Stage Products, H1 2012 13
Mid Clinical Stage Products, H1 2012 14
Discovery and Pre-Clinical Stage Products, H1 2012 15
Assessment by Monotherapy Products, H1 2012 23
Assessment by Combination Products, H1 2012 24
Assessment by Route of Administration, H1 2012 25
Assessment by Stage and Route of Administration, H1 2012 26
Assessment by Molecule Type, H1 2012 27
Assessment by Stage and Molecule Type, H1 2012 28
